Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Embarking on the quest to lose weight can be a risky business. Yo-yo dieting, compulsive binging, muscle wasting and brain ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Britain is in the grip of a gastric flu outbreak which has spread from hospitals in Scotland to the south coast, health chiefs said today. Levels of the virus, which has already affected 12 ...

Template biosynthesis of polypeptide chains on ribosomes usually does not produce a functional protein. The newly developed polypeptide chain must undergo certain chemical modifications outside the ...